AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's DiseaseGlobeNewsWire • 07/25/24
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024GlobeNewsWire • 05/28/24
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/13/24
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's DiseaseBusiness Wire • 05/13/24
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 03/14/24
Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a TurnaroundZacks Investment Research • 01/30/24
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseasesGlobeNewsWire • 01/03/24
AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b TrialGlobeNewsWire • 12/15/23
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFOGlobeNewsWire • 12/01/23
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/03/23
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023GlobeNewsWire • 11/02/23
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease DiagnosticGlobeNewsWire • 10/27/23